IMPACT OF HIGH SENSITIVITY TROPONIN ON THE EVALUATION AND TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

2017 HsTnT@0,5x.png

In this EMCREG-International Monograph, Impact of High Sensitivity Troponin on the Evaluation and Treatment of Acute Coronary Syndrome, you will find a detailed discussion regarding the use of high sensitivity troponin assays in patients presenting to the hospital with ACS from multiple perspectives including Emergency Medicine, Cardiology, Hospital Medicine, Laboratory Medicine, and Emergency Nursing. High sensitivity assays for troponin have been available for clinical use in Europe for the past decade and proved to be critical for the early diagnosis of acute myocardial necrosis in patients presenting to the emergency department (ED) with possible ACS and defining treatment for these patients which includes anti-platelet and anti-coagulant agents, as well as cardiologist intervention. In March 2017, high sensitivity cardiac troponin T was approved by the FDA for routine clinical use in the United States. Clearly many clinicians and laboratorians in the US have not had experience with high sensitivity troponin assays which has identified an important educational area for emphasis. This information on high sensitivity troponin becomes extremely important to emergency physicians, cardiologists, hospitalists, laboratorians, physician assistants, nurse practitioners, and emergency nurses as they routinely care for these often critically-ill patients.